Latest From Biotech Now

#BIO2014 Blogger Roundup

Official Blogger

Want to know what’s happening at the 2014 BIO International Convention? Find out from our bloggers! #BIO2014 Opening Reception: What A Night!, San Diego Biotechnology Network BIO 2014: Training Bio-Entrepreneurs to Use Coffee, Yoga, and Data, Xconomy Liking, Sharing, and Tweeting to Better Health, The Campaign for Modern Medicines Bioethics in Compassionate Use of Drugs, Sciberomics Drug Development: An Ethical Minefield, Sciberomics National Bioscience Report Shows Industry Robust with Strong Prospects for Growth, Bravo Group Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Therapeutic Licensing and M&A Deals

lab_tech

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Gates Foundation Issues Biotech Call to Action

Mundel

Today, Trevor Mundel from the Bill & Melinda Gates Foundation discussed the untapped potential of biotech companies to help develop new and better drugs, vaccines, diagnostics, and delivery systems for global health solutions at the 2014 BIO International Convention. This is important because 90 percent of the global infectious disease burden is borne by those who live in developing countries, yet the foundation believes that little attention is paid to health solutions to address these Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Patent Parameters

Untitled-1

Supreme Court Finds Naturally Occurring DNA to Be Patent Ineligible Last summer, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., which concerned the patent eligibility of the BRCA1 and BRCA2 genes. In Myriad, a unanimous Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Court also determined, albeit with one caveat, that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Reimbursement Considerations for Early Stage Companies

cells115x76

Panelists at Tuesday’s breakout session – Reimbursement Considerations for Early Stage Companies – overwhelmingly agreed that emerging biotech companies must consider reimbursement at the earliest stages of development. Christopher de Wolff, MSFS, Consultant, Numerof & Associates, Inc. moderated the panel and kicked it off by pointing out that many drugs achieve regulatory approval yet fail when they reach the market because of a lack of data and evidence directed at reimbursement. He asserted that the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,